BeOne Medicines
Nasdaq ONC · Basel, Switzerland
Works in Cardiovascular · Dermatology · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Oncology · Renal & urogenital · Respiratory · Women's health
BeOne Medicines is a clinical trial sponsor based in Basel, Switzerland, listed as Nasdaq ONC. It has 51 active clinical trials with 14,554 planned participants, across 11 therapeutic areas. Since 2021 it has completed 4 trials and stopped 5 early.
Trial track record · since 2021
Financials · Nasdaq ONC
Pipeline · 51 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
2 approved drug applications with a product on the market.
Questions about BeOne Medicines
BeOne Medicines is lead sponsor of 51 active clinical trials on ClinicalTrials.gov, with 14,554 planned participants, in Cardiovascular, Dermatology, GI & liver, Hematology and other areas. Since 2021 it has completed 4 trials and stopped 5 early.
BeOne Medicines is based in Basel, Switzerland and is listed as Nasdaq ONC. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with BeOne Medicines; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-16.
Approve Suite is not affiliated with BeOne Medicines.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.